Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Tamsulosin: Mechanism, Evidence, and Research Use
2026-09-24
Tamsulosin is a selective α₁A-adrenergic receptor antagonist used in smooth muscle relaxation studies and urological disease research. A meta-analysis of randomized surgical trials found lower postoperative urinary retention risk with tamsulosin, while the best regimen and the relevance of clinical dosing to laboratory experiments remain distinct questions.
-
PRKX-Mediated PD-L1 Stabilization in Gastric Cancer
2026-09-24
A single-cell and functional study defines immunosuppressive and immune-activated gastric cancer subtypes and identifies PRKX as a regulator of PD-L1 stability. The findings connect PRKX activity with T-cell exhaustion and poorer anti-PD-1 outcomes, while suggesting PRKX-targeted siRNA as a combination strategy that warrants further validation.
-
Proteasome Inhibition Drives Thymic Regeneration
2026-09-23
A 2026 study identifies proteasome inhibition as a route to increasing FOXN1 in thymic epithelial cells and accelerating recovery after radiation injury in mice. Nitazoxanide emerged as a comparatively viability-preserving compound, linking proteasome inhibition to an adaptive ER-stress response and autophagy; translation beyond the tested mouse setting remains to be established.
-
PR-619: Reversible Deubiquitylating Enzymes Inhibitor
2026-09-23
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor that increases intracellular ubiquitinated proteins without directly inhibiting proteasomal catalytic activity. Its broad DUB activity supports ubiquitination pathway research, autophagy assays, cancer biology research, and neurodegenerative disease models, but cytotoxicity, solvent dependence, and limited selectivity require controlled interpretation.
-
PSI-7977 in Redox-Aware Assay Design
2026-09-22
PSI-7977 is best understood as a targeted antiviral nucleotide-prodrug tool, not a direct regulator of BAP1, SLC7A11, or disulfidptosis. This article explains how to place PSI-7977 in a rigorous parallel assay strategy informed by recent findings on cystine stress, NADPH depletion, and tumor-suppressor biology.
-
Spinal EAATs and Connexin 43 in Breakthrough Cancer Pain
2026-09-22
Jiang and colleagues establish a modified endothelin-1 model of breakthrough cancer pain and identify coordinated changes in spinal astrocytic EAATs and connexin 43 signaling. The findings position glutamate clearance and astrocytic gap junction activity as mechanistically linked targets for studying cancer pain hypersensitivity.
-
NSC-23766: Rac GTPase Inhibitor Workflows
2026-09-21
NSC-23766 is a practical Rac GTPase inhibitor for separating Rac1-dependent signaling from downstream effects in cancer, endothelial, and stem/progenitor-cell models. This guide translates its mechanism into dose-finding, pathway-validation, combination, barrier-function, and troubleshooting workflows.
-
Lamotrigine: A Mechanism-Aware Assay Guide
2026-09-21
Lamotrigine research is strongest when target pharmacology, solvent behavior, and pathway attribution are interpreted together. This guide connects sodium-channel and serotonin assays with a metabolism-aware experimental framework inspired by recombinant-enzyme and HPLC-MS methodology.
-
Maternal Deltamethrin Exposure and Hippocampal Ferroptosis
2026-09-20
A 2025 study shows that maternal deltamethrin exposure during pregnancy and lactation disrupts learning and memory in male rat offspring through hippocampal ferroptosis linked to the p53–SLC7A11/GPX4 axis. By combining behavioral testing, hippocampal pathology, biochemical analyses, calcium-signaling measurements, and HT-22 cell experiments, the work provides a mechanistic framework for developmental neurotoxicology research.
-
From Ocular Angiogenesis to IL-7 mRNA Strategy
2026-09-19
A translational framework linking glial–vascular biology, SOCS3 signaling, and a hypothesis-driven use of EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag) in preclinical research.
-
RHEB Neddylation Activates mTORC1 in Liver Cancer
2026-09-18
The reference study identifies RHEB as a non-cullin substrate of the UBE2F-SAG neddylation machinery and maps this modification to enhanced lysosomal signaling, GTP binding, and mTORC1 activity. Cellular, mouse, and hepatocellular carcinoma data connect the pathway to liver steatosis, tumorigenesis, and patient survival, while also defining important limits for therapeutic interpretation.
-
BoNT/A, SOCS3, and Ocular Angiogenesis
2026-09-18
A 2024 study found that intravitreal botulinum neurotoxin serotype A reduced laser-induced choroidal neovascularization in mice while suppressing retinal glial activation, increasing Socs3, and lowering Vegfa expression. Loss of neuronal or glial SOCS3 weakened this protection, identifying glial SOCS3 signaling as a mechanistically relevant link between neural injury responses and pathological ocular angiogenesis.
-
Carbapenemase Gene Transmission in Enterobacter cloacae
2026-09-17
Chen et al. mapped carbapenemase-encoding genes, their chromosomal or plasmid locations, transferability, mobile genetic elements, and strain relatedness in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. The findings identify plasmid-associated blaNDM-1 as a major dissemination concern and show why resistance surveillance should combine molecular localization, conjugation testing, susceptibility profiling, and genotyping.
-
Vacuolin-1 Workflows for Reliable Lysosomal Assays
2026-09-17
Learn how Vacuolin-1 (SKU C4084) can improve experimental interpretation in lysosomal exocytosis, membrane repair, and cell viability workflows. This scenario-based guide covers assay design, protocol parameters, data controls, and practical reagent-selection criteria.
-
X-Gal: From Colony Color to Assay Confidence
2026-09-16
X-Gal is more than a blue-white colony screening reagent: it is a spatial, qualitative readout of β-galactosidase activity. This guide connects its chemistry and lacZα logic with orthogonal assay design inspired by recent iRhom2 olfaction research.